The DEVELOPMENT OF A VALIDATED STABILITY INDICATING LC-MS METHOD FOR THE DETERMINATION OF TENOFOVIR DISOPROXIL FUMARATE USING QUALITY BY DESIGN APPROACH
Keywords:Box-Behnken design, LC-MS, Method development QbD, Resolution V irregular fraction design, Tenofovir disoproxil fumarate, Validation
Objective: To develop a validated Liquid Chromatography-Mass Spectrometry (LC-MS) method through Quality by Design (QbD) approach for the determination of tenofovir disoproxil fumarate (tenofovir DF) in bulk, pharmaceutical formulation and stress conditions.
Methods: The analytical target profile (ATP) was to develop a simple, accurate, precise, specific, and robust method with the Critical Quality Attribute (CQA) being retention time, theoretical plate and peak tailing. Derived from the risk assessment studies, four high-risk factors were screened using resolution V irregular fraction design. Organic modifier strength, flow rate and injection volume were further optimized using Box-Behnken design (BBD). The optimized method condition was validated and applied for the determination of the analyte in pharmaceutical formulation. The stability of the analyte in stress conditions was determined. All experiments were performed using reverse-phase Acquity UPLC BEH C18 (1.7 µm, 1 mm X 50 mm) column coupled in-line with Synapt G2 mass spectrometer in positive electrospray ionization (ESI) mode with electron multiplier analog-to-digital detector.
Results: Optimized method condition eluted analyte at 3.40 min and the m/z 520 ratified the analyte peak. The method was validated and was found to be specific, linear in the range of 20-100 µg/ml (R2 = 0.9998) with accuracy between 98.71% - 101.17% and precise. The limit of detection and quantification were 5.50 µg/ml and 16.68 µg/ml respectively. Analyte degraded completely in acid and basic environment, however, stable in oxidative and photolytic conditions.
Conclusion: The validated method developed through the systematic and rational QbD approach bespoke superior quality. The QbD approach not only justified the entire process but also eliminated uncertainties.
Tabora JE, Domagalski N. Multivariate analysis and statistics in pharmaceutical process research and development. Annu Rev Chem Biomol Eng 2017;8:403–26.
Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J 2014;16:771–83.
Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci 2017;12:1–8.
Grewal NK, Leadbeater NE. The central role of chemistry in ‘quality by design’ approaches to drug development. Future Med Chem 2012;4:1799–810.
Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Sci 2011;100:797–812.
Hecht ES, Oberg AL, Muddiman DC. Optimizing mass spectrometry analyses: A tailored review on the utility of design of experiments. J Am Soc Mass Spectrom 2016;27:767–85.
Lyseng Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005;65:413–32.
Pozniak A. Emtricitabine/tenofovir disoproxil fumarate: a viewpoint by anton pozniak. Drugs 2004;64:2083–4.
Nozza S, Poli A, Ripa M, Galli L, Chiappetta S, Spagnuolo V, et al. Efficacy of elvitegravir/cobicistat/emtricitabine/eenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors’ response. J Antimicrob Chemother 2017; 72:1549–50.
Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 2010;70:2315–38.
Clercq ED. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. Expert Opin Pharmacother 2009;10:2935–7.
Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, et al. Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 2017;72:2042–8.
Xu P, Wang Y, Qin Z, Qiu L, Zhang M, Huang Y. Combined medication of antiretroviral drugs tenofovir disoproxil fumarate, emtricitabine and raltegravir reduces neural progenitor cell proliferation in vivo and in vitro. J Neuroimmune Pharmacol 2017;12:682–92.
Mizushima D, Nguyen DTH, Nguyen DT, Matsumoto S, Tanuma J, Gatanaga H, et al. Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease. J Infect Chemother 2018;24:549–54.
Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarninim SA, et al. Hepatitis B virus infection. Nat Rev Dis Primer 2018;4:1-20.
Shaheen AA, Al Mattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir Ddisoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther 2017;46:599–604.
Atul S, Charushila B, Surana Sanjay. Application of UV-spectrophotometric methods of estimation of tenofovir disoproxil fumarate in tablets. Pak J Pharm Sci 2009;22:27-9.
Al-Johar HI, Maher HM, Al-Zoman NZ, Al-Shammary DJ, Al-Showiman HA. Stability-indicating capillary electrophoresis method for the determination of emtricitabine and tenofovir disoproxil fumarate in pharmaceutical tablets. Acta Chromatogr 2017;29:469–76.
Ramaswamy A, Arul Gnana Dhas AS. Development and validation of an analytical method for the quantitation of emtricitabine, tenofovir, efavirenz-based on HPLC. Arab J Chem 2018;11:275–81.
Zhang Z, Wang L, Xu X, Dong Y, Zhang L. Development of a validated HPLC method for the determination of tenofovir disoproxil fumarate using a green enrichment process. Anal methods 2015;7:6290–8.
Dutta Tejaswi JK, Rajan RG. Reverse-phase high-performance liquid chromatography method development and validation for simultaneous estimation and forced degradation studies of emtricitabine, rilpivirine, and tenofovir alafenamide in solid dosage form. Asian J Pharm Clin Res 2019;12:112-6.
Babu C, Devanna N, Reddy KVS. Validated gradient stability indicating rp-hplc method for the simultaneous quantification of 11 related substances in the combined dosage forms of lamivudine and tenofovir disopeoxil fumarate. Int J Appl Pharm 2017;9:61-8.
PRNL, PP, Sk M, NR, Rao M, VB. UPLC separation analysis of emtricitabine, tenofovir, cobicistat and elvitegravir from their degradation products. Int J Pharm Pharm Sci 2016;8:362-9.
BVP, Reddy T, VB, YS, DR. Simultaneous determination of antiretroviral drugs emtricitabine and tenofovir desoproxil fumarate by stability indicating RP-HPLC method. Int J Pharm Pharm Sci 2015;7:390-8.
Meesters RJW, Van Kampen JJA, Scheuer RD, Van der Ende ME, Gruters RA, Luider TM. Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry. J Mass Spectrom 2011;46:282–9.
Illamola SM, Valade E, Hirt D, Dulioust E, Zheng Y, Wolf JP, et al. Development and validation of a LC–MS/MS method for the quantification of tenofovir and emtricitabine in seminal plasma. J Chromatogr B 2016;1033:234–41.
Barreiros L, Cunha Reis C, Silva EMP, Carvalho JRB, Das Neves J, Sarmento B, et al. Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids. J Pharm Biomed Anal 2017;136:120–5.
Ocque AJ, Hagler CE, Morse GD, Letendre SL, Ma Q. Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fuid. J Pharm Biomed Anal 2018;156:163–9.
Valluru RK, B PB, S KS, V PK, Kilaru NB. High throughput LC–MS/MS method for simultaneous determination of tenofovir, lamivudine and nevirapine in human plasma. J Chromatogr B 2013;931:117–26.
Kurmi M, Golla VM, Kumar S, Sahu A, Singh S. Stability behavior of antiretroviral drugs and their combinations. 1: Characterization of tenofovir disoproxil fumarate degradation products by mass spectrometry. RSC Adv 2015;5:96117–29.
Kenett RS, Kenett DA. Quality by design applications in biosimilar pharmaceutical products. Accreditation Qual Assur 2008;13:681–90.
Charoo NA, Ali AA. Quality risk management in pharmaceutical development. Drug Dev Ind Pharm 2013;39:947–60.
Hibbert DB. Experimental design in chromatography: a autorial review. J Chromatogr B 2012;910:2–13.
ICH Harmonised tripartite guideline, validation of analytical procedures: Text and Methodology Q2(R1); 2005.
Sirisha T. Bio-analytical liquid chromatographic determination of some selected chiral drugs in pharmaceutical dosage forms [dissertation on the internet]. Mysuru: JSS University. Available from: https://shodhganga.inflibnet.ac.in/handle/10603/176394. [Last accessed on 15 Oct 2018].
ICH Harmonised Tripartite Guideline, Stability testing of new drug substances and products Q1A(R2); 2003.
FDA, Guidance R. Validation of chromatographic methods. center for drug evaluation and research (CDER), Food and Drug Administration; 1994.
Government of India, Ministry of Health. Pharmacopoeia of India; 2018.
National Center for Biotechnology Information [Internet]. PubChem Compound Database. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/464205. [Last accessed on 10 Feb 2019]
Rao NM, Sankar DG. Development and validation of stability-indicating HPLC method for simultaneous determination of lamivudine, tenofovir, and dolutegravir in bulk and their tablet dosage form. Future J Pharm Sci 2015;1:73-7.